← All Signals

🏥 FDA: Radnostix — Class III

healthcareneutralSource: FDA
70%Confidence
0Views
FDASource
2026-04-14Date

Summary

Radnostix's Class III recall for failed capsule specifications in a diagnostic kit component is a low-risk issue but indicates manufacturing inconsistencies. This may have minimal market impact but could affect niche diagnostic procedures.

Actionable: Monitor for any follow-up recalls in Radnostix's product lines.

AI Confidence: 70%

Data Points

firmRadnostix
classificationClass III
statusOngoing
distributionNationwide in the US, including Puerto Rico
productGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, Internation

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now